UBS Starts Tandem Diabetes Care (TNDM) at Neutral

UBS initiates coverage on Tandem Diabetes Care (NASDAQ: TNDM) with a Neutral rating.

The analyst is coming out bullish on the US Medical Supplies and Devices (MedTech) sector and comments "We expect continued outperformance versus the S&P 500 and broader healthcare in 2019 and see the sector as particularly well positioned in a market where investors are concerned about deceleration, given the durability of MedTech growth through the cycle. Our top picks for quality/momentum/growth are BSX and ABT in the large cap space and MASI, VAR, and TFX in the mid-caps. For value/FCF we like HRC and MDT and call out dividend/capital allocation upside at BAX, initiating with Buy ratings."

For an analyst ratings summary and ratings history on Tandem Diabetes Care click here. For more ratings news on Tandem Diabetes Care click here.

Shares of Tandem Diabetes Care closed at $33.83 yesterday.

You May Also Be Interested In

• Reddit to join S&P 500 index on Aug. 18, shares leap
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform
• BMO Capital Starts Energy Fuels (UUUU) at Outperform